Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2019 10:00 ET | Source: Zoom Video Communications

Zoom and HP Collaborate to Create Modern Workspaces for Today’s Workforce

SAN JOSE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. today announced a partnership with HP Inc. to meet the collaboration needs of today’s teams for video-first...
November 29, 2018 06:00 ET | Source: Invivoscribe, Inc.

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
November 28, 2018 04:53 ET | Source: Invivoscribe, Inc.

Invivoscribe reicht Anträge für das LeukoStrat CDx FLT3-Mutations-Assay sowohl in den USA als auch in Japan ein, um die Anträge von Daiichi Sankyo für Quizartinib zu unterstützen

SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Invivoscribe freut sich bekanntgeben zu können, dass das Unternehmen zur Unterstützung einer laufenden Partnerschaft mit Daiichi Sankyo für den...
November 27, 2018 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
November 19, 2018 08:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
September 28, 2018 01:42 ET | Source: Invivoscribe, Inc.

Invivoscribe® erhält in Japan die Zulassung für seinen LeukoStrat® CDx FLT3-Mutations-Assay zur Beurteilung von Patienten mit akuter myeloischer Leukämie (AML), die mit Xospata® (Gilteritinib-Fumarat) behandelt werden können

SAN DIEGO, Kalifornien, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., ein weltweit tätiges Unternehmen, das Biomarker- und Klonalitätsstest für die Bereiche Onkologie und personalisierte...
September 27, 2018 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine®...
May 24, 2018 09:00 ET | Source: Nuxeo Corporation

Nuxeo Named One of Inc. Magazine’s 2018 Best Workplaces

NEW YORK, May 24, 2018 (GLOBE NEWSWIRE) -- Nuxeo, the leading cloud-native Content Services Platform, today announced the company’s selection as one of Inc. Magazine’s Best Workplaces for 2018, the...
May 16, 2018 04:28 ET | Source: Invivoscribe, Inc.

Invivoscribe เปิดตัว LymphoTrack Dx TRB Assay เป็นชุด CE-Marked IVD สร้างเสร็จชุด NGS Clonality Suite สำหรับแพลตฟอร์ม MiSeq

เมืองซานดิเอโก วันที่, May 16, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc. บริษัทระดับโลกที่มีประสบการณ์ยาวนานหลายสิบปีในการจัดทำการโคลนนิ่งและโซลูชั่นการทดสอบ biomarker...
May 16, 2018 04:28 ET | Source: Invivoscribe, Inc.

Invivoscribe發佈獲得CE認證的體外診斷套盒LymphoTrack Dx TRB檢定盒，為MiSeq平台的下一代測序克隆套件再添新成員

美國聖地亞哥, May 16, 2018 (GLOBE NEWSWIRE) -- 在為腫瘤學和個性化分子醫學領域提供克隆和生物標記測試解決方案上擁有數十年經驗的全球性企業Invivoscribe Technologies Inc.今日發佈了用於Illumina®MiSeq®平台的LymphoTrack®Dx TRB...